Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528022 | 0.87 | KMT2A (0.44) | KMT2AMEN1CYP11B1CYP11B2FDPS | |
| SCHEMBL4759513 | 0.84 | KMT2A (0.42) | KMT2AMEN1CYP11B1CYP11B2FDPS | |
| SCHEMBL1845371 | 0.83 | KMT2A (0.43) | KMT2AMEN1CYP11B1CYP11B2FDPS | |
| SCHEMBL6948425 | 0.83 | KMT2A (0.43) | KMT2AMEN1CYP11B1CYP11B2KCNN4 | |
| SCHEMBL8188378 | 0.83 | KMT2A (0.46) | KMT2AMEN1CYP11B1CYP11B2KCNN4 | |
| SCHEMBL6467815 | 0.83 | KMT2A (0.43) | KMT2AMEN1CYP11B1CYP11B2FDPS | |
| SCHEMBL5327785 | 0.83 | KMT2A (0.43) | KMT2AMEN1CYP11B1CYP11B2FDPS | |
| SCHEMBL6446028 | 0.82 | KMT2A (0.43) | KMT2AMEN1CYP11B1CYP11B2FDPS | |
| SCHEMBL8806580 | 0.80 | KMT2A (0.44) | KMT2AMEN1CYP11B1CYP11B2KCNN4 | |
| SCHEMBL27544681 | 0.80 | KMT2A (0.41) | KMT2AMEN1CYP11B1CYP11B2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994283-A | Beta-D-galactopyranose compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2020260857-A1 | HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2020-12-30 | — | — | WO | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-9650371-B2 | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9650371-B2 | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20160326158-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326158-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160108052-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160108052-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2016-04-21 | — | — | US | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-11-02 | — | — | US | disclosed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | disclosed |
| EP-1537096-A2 | DERIVATIVES OF DIOXANE-2-ALKYL CARBAMATES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004020430-A2 | DERIVATIVES OF DIOXANE-2-ALKYL CARBAMATES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-03-11 | — | — | WO | disclosed |
| US-5565479-A | IMIDAZOLYL FUSED THIAZOLES ANTISEROTONINE AGENT | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-10-15 | — | — | US | disclosed |
| EP-0666263-A1 | NOVEL CONDENSED THIAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108052-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | KMT2A 2134/4885MEN1 1637/4885CYP11B1 1188/4885 |
| US-20160326158-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | KMT2A 2242/4885MEN1 1661/4885CYP11B1 1169/4885 |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | KMT2A 3293/4885MEN1 1600/4885CYP11B1 94/4885 |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | KMT2A 2015/4885MEN1 2050/4885CYP11B1 145/4885 |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | CHRM3, CHRM2, CHRM4 | KMT2A 3209/4885MEN1 1380/4885CYP11B1 67/4885 |
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | KMT2A 1825/4885MEN1 3073/4885CYP11B1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.